Volume 28, Issue 2 pp. 430-437
Original Article

Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus

Y.-Hu. Chang

Y.-Hu. Chang

Lee’s Endocrinology Clinic, Pingtung, Taiwan

Y.-Hu. Chang and S.-J. Yen contributed equally as first authors.

Search for more papers by this author
S.-J. Yen

S.-J. Yen

Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Y.-Hu. Chang and S.-J. Yen contributed equally as first authors.

Search for more papers by this author
Y.-Ha. Chang

Y.-Ha. Chang

Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

Search for more papers by this author
W.-J. Wu

W.-J. Wu

Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Search for more papers by this author
K.-D. Lin

Corresponding Author

K.-D. Lin

Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence: K.-D. Lin, Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, No.100, Shin-Chuan 1st Road, Sanmin Dist., Kaohsiung, Taiwan (tel.: +886-7-3121101#7375; fax: +886-7-3122810; e-mail: [email protected]).

Search for more papers by this author
First published: 23 September 2020
Citations: 27

Abstract

Background and purpose

The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear. No study has examined the interaction between pioglitazone and statin treatment on prevention of PD. This study analyzed the associations between pioglitazone, statins, and the incidence of PD in patients with diabetes mellitus (DM) in Taiwan.

Methods

We used the National Health Insurance database from 1996 to 2013. DM and PD were diagnosed according to the International Classification of Diseases, Ninth Revision, Clinical Modification codes. We used the propensity score-matching method to match the study groups. Cox regression analyses were employed to calculate the relative risk of the incidence of PD.

Results

There were 48 828 patients matched and categorized equally into the pioglitazone group and the non-pioglitazone group. The number of PD patients in the pioglitazone group and the non-pioglitazone group was 275 (1.1%) and 417 (1.7%), respectively. The pioglitazone group had a lower incidence of PD, with an adjusted hazard ratio (aHR) of 0.66 [95% confidence interval (CI): 0.57–0.78], and this benefit was dose-dependent. Of note, as compared with either pioglitazone or statin treatment, our results first showed that the combination of pioglitazone and statins further lowered the risk of PD, with an aHR of 0.78 (95% CI: 0.64–0.94; P = 0.010).

Conclusions

Our study results suggested that pioglitazone could be a promising agent for reducing the incidence of PD in patients with DM, and works synergistically with statins.

Disclosure of conflicts of interest

The authors declare no financial or other conflicts of interest.

Data availability statement

All data were obtained from the NHI database. The data-sharing agreements forbid onward sharing of individual-level data. Aggregated summary data may be available from the corresponding author, where the data requested are considered appropriate and relevant to this study.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.